Human medicines European public assessment report (EPAR): Neuzafy, filgrastim, Status: Opinion
New Medicines and Opinions: Neuzafy (filgrastim) What is established Neuzafy is a biosimilar medicinal product containing filgrastim, a recombinant granulocyte colony-stimulating factor (G-CSF). Filgrastim works by stimulating the bone marrow to increase production and maturation of neutrophils, a type of white blood cell important in fighting infections. Its active mechanism targets the…
Human medicines European public assessment report (EPAR): Kizfizo, temozolomide, Status: Opinion
Kizfizo (Temozolomide): New European Medicines Agency Opinion on Treatment for Glioma This dossier examines the recent positive opinion issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) regarding Kizfizo, a new formulation of the chemotherapy drug temozolomide. The medicine is intended primarily for treating glioblastoma multiforme and…
Human medicines European public assessment report (EPAR): Fovlussea, ranibizumab, Ophthalmologicals, Status: Opinion
What is established On 15 October 2026, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the granting of marketing authorization for Fovlussea, a biosimilar drug to ranibizumab. Ranibizumab is a monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A), a key…
Human medicines European public assessment report (EPAR): Remicade, infliximab, Date of authorisation: 13/08/1999, Revision: 70, Status: Authorised
What is established Remicade (active substance infliximab) is a monoclonal antibody medicine authorised in the European Union since 1999. It is used primarily as an anti-inflammatory treatment in several autoimmune diseases where inflammation is pathological, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis. Infliximab works by targeting…
Human medicines European public assessment report (EPAR): Idelvion, albutrepenonacog alfa, Date of authorisation: 11/05/2016, Revision: 14, Status: Authorised
Health & Science Evidence Dossier: Idelvion (albutrepenonacog alfa) for Haemophilia B What is established Idelvion is a medicinal product authorized for use in the European Union to prevent and treat bleeding episodes in patients with haemophilia B, an inherited disorder characterized by a deficiency of clotting Factor IX. The active ingredient, albutrepenonacog…
Human medicines European public assessment report (EPAR): Stelara, ustekinumab, Date of authorisation: 16/01/2009, Revision: 54, Status: Authorised
What is established Stelara (ustekinumab) is a monoclonal antibody drug authorized in the European Union since 2009 for the treatment of several inflammatory diseases including moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn’s disease, and ulcerative colitis. It targets two immune system messenger molecules, interleukin 12 (IL-12) and interleukin 23 (IL-23),…
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2026
What is established In October 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended approval of six new medicines, including treatments for metastatic pancreatic cancer, obesity and type 2 diabetes, achondroplasia in children, and brain tumors in adults and children. The committee also supported extensions of…